Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Linezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.69 |
| ▸ | MAOA | P21397 | 5/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.69 |
| ▸ | SDHA | P31040 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CALML3 | P27482 | 1/20 | 0.69 |
| ▸ | F10 | P00742 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eperezolid SCHEMBL5820845 | 0.91 | MAOB (0.55) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30226927 | 0.83 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30638355 | 0.83 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2222512 | 0.83 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL7992562 | 0.83 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL374752 | 0.83 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5027 | 0.83 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5524444 | 0.83 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL1561095 | 0.83 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL14966322 | 0.82 | MAOB (0.94) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104086633-B | Short fatty acid tail polymyxin derivatives and application thereof | 北方抗生素有限公司 | 2018-02-09 | — | — | CN | claimed |
| EP-3263586-A1 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF | Northern Antibiotics Oy (FI) | 2018-01-03 | — | — | EP | claimed |
| EP-3078672-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | Northern Antibiotics Oy (FI) | 2016-10-12 | — | — | EP | claimed |
| EP-2057185-B1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS OY (FI) | 2016-05-11 | — | — | EP | claimed |
| CN-101970461-B | Short-chain fatty acid tail polymyxin derivatives and uses thereof | NORTHERN ANTIBIOTICS LTD | 2015-04-08 | — | — | CN | claimed |
| CN-103059106-B | Polymixin derivative and application thereof | NORTHERN ANTIBIOTICS LTD | 2015-01-14 | — | — | CN | claimed |
| US-8680234-B2 | Polymyxin derivatives and uses thereof | NORTHERN ANTIBIOTICS OY (FI) | 2014-03-25 | — | — | US | claimed |
| US-20100292136-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS OY (FI) | 2010-11-18 | — | — | US | claimed |
| EP-2242765-A1 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF | Northern Antibiotics Oy (FI) | 2010-10-27 | — | — | EP | claimed |
| US-7807637-B2 | Polymyxin derivatives and uses thereof | NORTHERN ANTIBIOTICS OY (FI) | 2010-10-05 | — | — | US | claimed |
| EP-2032521-B1 | NEW METHOD FOR SALT PREPARATION | SANDOZ AG (CH) | 2009-10-28 | — | — | EP | claimed |
| WO-2009098357-A1 | SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS OY (FI) | 2009-08-13 | — | — | WO | claimed |
| EP-2057185-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | Northern Antibiotics Oy (FI) | 2009-05-13 | — | — | EP | claimed |
| EP-2032521-A2 | NEW METHOD FOR SALT PREPARATION | Sandoz AG (CH) | 2009-03-11 | — | — | EP | claimed |
| US-20080287345-A1 | Polymyxin derivatives and uses thereof | NORTHERN ANTIBIOTICS OY (FI) | 2008-11-20 | — | — | US | claimed |
| WO-2008017734-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS OY (FI) | 2008-02-14 | — | — | WO | claimed |
| WO-2008000418-A2 | NEW METHOD FOR SALT PREPARATION | SANDOZ AG (CH) | 2008-01-03 | — | — | WO | claimed |
| US-20240208958-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2001070955-A2 | IDENTIFICATION OF ESSENTIAL GENES IN PROKARYOTES | ELITRA PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001034810-A2 | GENES ESSENTIAL FOR MICROBIAL PROLIFERATION | ELITRA PHARMACEUTICALS, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208958-A1 | OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT | OXA1L, IL17A, TBCD | MAOB 681/4885MAOA 1126/4885PTGS1 2243/4885 |
| US-20100292136-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | C5, C9, C3AR1 | MAOB 2514/4885MAOA 3130/4885PTGS1 3266/4885 |
| US-20080287345-A1 | Polymyxin derivatives and uses thereof | C9, C5, C3AR1 | MAOB 2355/4885MAOA 2982/4885PTGS1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.